NCT05481658View on ClinicalTrials.gov

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

PHASE1RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Cutaneous Metastases

Interventions

DRUG

Diphencyprone (DPCP)

topical immunomodulator

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors

lead

Nicholas Gulati

OTHER